サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：白血病治療薬の世界市場（2022年～2028年）
市場調査レポート
商品コード
1159350

白血病治療薬の世界市場（2022年～2028年）

Leukemia Therapeutic Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 125 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
白血病治療薬の世界市場（2022年～2028年）
出版日: 2022年10月17日
発行: Orion Market Research
ページ情報: 英文 125 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の白血病治療薬の市場規模は、予測期間中に7.3%という大幅なCAGRで成長すると予測されています。世界の白血病治療薬市場の成長に貢献する顕著な要因としては、様々な治療法の活用によって日々進歩するがん治療における、需要と満たされていない医療ニーズに焦点を当てていることが考えられます。さらに、研究開発への支出の増加、生活の質の優位性への注目の高まり、医療に対する政府による投資の増加、薬剤開発を強化するための薬理学の進歩は、同市場の成長を促進する要因となっています。

当レポートでは、世界の白血病治療薬市場について調査し、市場の概要とともに、競合情勢、セグメント別の市場、地域別分析、および企業プロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と考察

  • 調査範囲
  • アナリストによる考察と現在の市場動向

第3章 競合情勢

  • 主要企業分析

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の白血病治療薬市場：薬剤タイプ別
    • 急性骨髄性白血病（AML）
    • 慢性骨髄性白血病（CML）
    • 急性リンパ性白血病（ALL）
    • 慢性リンパ性白血病（CLL）
  • 世界の白血病治療薬市場：治療タイプ別
    • 化学療法
    • 免疫療法
    • 標的療法
    • その他

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • Agios Pharmaceuticals
  • Astellas Pharma Inc.
  • Biogen Inc
  • Bristol Myers Squibb
  • Cephalon A/S
  • Daiichi Sankyo
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche Ltd
  • GSK Plc
  • Innate Pharma Sa
  • Johnson & Johnson
  • Merck KGgaAa (The Merck Group)
  • Neomed Management AS
  • Novartis
  • Pfizer
  • Sanofi
  • Spectrum Pharmaceuticals Inc.
  • Viracta Therapeutics Inc.
図表

LIST OF TABLES

  • 1. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028($ MILLION)
  • 2. GLOBAL ACL THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL CML THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL ACL THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL CLL THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE , 2021-2028 ($ MILLION)
  • 7. GLOBAL CHEMOTHERAPY IN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL IMMUNOTHERAPY IN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 9. GLOBAL TARGETED THERAPY IN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL OTHER TRETAMENT TYPE IN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 11. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
  • 12. NORTH AMERICAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE S, 2021-2028 ($ MILLION)
  • 15. EUROPEAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. EUROPEAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 17. EUROPEAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE S, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE S, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE S, 2021-2028 ($ MILLION)

 

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL LEUKEMIA THERAPEUTIC MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL LEUKEMIA THERAPEUTIC MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL LEUKEMIA THERAPEUTIC MARKET, 2021-2028 (%)
  • 4. GLOBAL LEUKEMIA THERAPEUTIC MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL CHRONIC MYELOID LEUKEMIA (CML) THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA (ALL) THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL LEUKEMIA THERAPEUTIC MARKET SHARE BY TREATMENT TYPES, 2021 VS 2028 (%)
  • 10. GLOBAL CHEMOTHERAPY IN LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL IMMUNOTHERAPY IN LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL TARGETED THERAPY IN LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL OTHER TREATMENT TYPE LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL OTHER DRUGS FOR LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. US LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINALEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SOUTH KOREA LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026473

Title: Global Leukemia Therapeutic Market Size, Share & Trends Analysis Report by Type (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia) by Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, and Others) ) Forecast 2022-2028.

The global leukemia therapeutic market is anticipated to grow at a substantial CAGR of 7.3% during the forecast period. Acute lymphocytic also known as blood cancer begins from an early version of white blood cells in the bone marrow. The term acute means that leukemia can progress very rapidly, and in case if not treated can be fatal in a few months. Cancer treatments have become advanced day by day, by the use of various therapies the demand and focusing on the unmet medical needs are the prominent factor responsible for the growth of the global leukemia therapeutics market. Moreover, increasing expenditure on research and development, rising focus on the superiority of quality of life, higher investment incurred by the government on healthcare, and advancement in pharmacology to enhance the drug development are factors propelling the growth of this market.

The global leukemia therapeutics market is segmented based on type, and treatment type. Based on type the market is bifurcated into acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia. Based on treatment type, the market is sub-segmented into chemotherapy, immunotherapy, targeted therapy, and others. .

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America region is anticipated to hold a major share in the global leukemia therapeutics market, due to a large number of patients pool suffering from cancer and the availability of a strong generic drug market in the emerging countries. In addition, manufacturers' interest in expanding to these North American countries, will further fuel the growth in the near future.

The major companies serving the global leukemia therapeutic market are Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb, Cephalon A/S, Daiichi Sankyo, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Novartis, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2021, Novartis announced that the US FDA approved Scemblix(asciminib) for the treatment of chronic myeloid leukemia(CML). The FDA approved this drug for adult patients with Philadelphia chromosome-positive CML in the chronic phase(Ph+CML-CP). Moreover, Scemblix recommends that patients with CML were previously treated with two or more tyrosine kinase inhibitors(TKIs), and reduced mutations at the defective BCR-ABL 1 gene, which is associated with the over-production of leukemic cells.

 

Research Methodology

The market study of the global leukemia therapeutic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Leukemia Therapeutic Market Research and Analysis by Types

2. Global Leukemia Therapeutic Market Research and Analysis by Drug Types

The Report Covers:

  • Comprehensive Research Methodology of the global leukemia therapeutic market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global leukemia therapeutic market.
  • Insights about market determinants that are stimulating the global leukemia therapeutic market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Leukemia Therapeutic Market
  • Recovery Scenario of Global Leukemia Therapeutic Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key CompanyAnalysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Leukemia Therapeutics Market by Drug Type
    • 4.1.1. Acute Myeloid Leukemia (AML)
    • 4.1.2. Chronic Myeloid Leukemia (CML)
    • 4.1.3. Acute Lymphocytic Leukemia (ALL)
    • 4.1.4. Chronic Lymphocytic Leukemia (CLL)
  • 5.2. Global Leukemia Therapeutics Market by Treatment TypeTreatment Type
    • 5.2.1. Chemotherapy
    • 5.2.2. Immunotherapy
    • 5.2.3. Targeted Therapy
    • 5.2.4. Other
      • 5.2.4.1.

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Agios Pharmaceuticals
  • 7.3. Astellas Pharma Inc.
  • 7.4. Biogen Inc
  • 7.5. Bristol Myers Squibb
  • 7.6. Cephalon A/S
  • 7.7. Daiichi Sankyo
  • 7.8. Eisai Co. Ltd
  • 7.9. F. Hoffmann-La Roche Ltd
  • 7.10. GSK Plc
  • 7.11. Innate Pharma Sa
  • 7.12. Johnson & Johnson
  • 7.13. Merck KGgaAa (The Merck Group)
  • 7.14. Neomed Management AS
  • 7.15. Novartis
  • 7.16. Pfizer
  • 7.17. Sanofi
  • 7.18. Spectrum Pharmaceuticals Inc.
  • 7.19. Viracta Therapeutics Inc.